Literature DB >> 25355884

Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo.

Chen Ling1, Yuan Wang2, Yuan Lu3, Lina Wang4, Giridhara R Jayandharan5, George V Aslanidi6, Baozheng Li6, Binbin Cheng7, Wenqin Ma6, Thomas Lentz8, Changquan Ling9, Xiao Xiao10, R Jude Samulski8, Nicholas Muzyczka11, Arun Srivastava12.   

Abstract

UNLABELLED: We have previously reported that the removal of a 20-nucleotide sequence, termed the D sequence, from both ends of the inverted terminal repeats (ITRs) in the adeno-associated virus serotype 2 (AAV2) genome significantly impairs rescue, replication, and encapsidation of the viral genomes (X. S. Wang, S. Ponnazhagan, and A. Srivastava, J Mol Biol 250:573-580, 1995; X. S. Wang, S. Ponnazhagan, and A. Srivastava, J Virol 70:1668-1677, 1996). Here we describe that replacement of only one D sequence in either ITR restores each of these functions, but DNA strands of only single polarity are encapsidated in mature progeny virions. Since most commonly used recombinant AAV vectors contain a single-stranded DNA (ssDNA), which is transcriptionally inactive, efficient transgene expression from AAV vectors is dependent upon viral second-strand DNA synthesis. We have also identified a transcription suppressor sequence in one of the D sequences, which shares homology with the binding site for the cellular NF-κB-repressing factor (NRF). The removal of this D sequence from, and replacement with a sequence containing putative binding sites for transcription factors in, single-stranded AAV (ssAAV) vectors significantly augments transgene expression both in human cell lines in vitro and in murine hepatocytes in vivo. The development of these genome-modified ssAAV vectors has implications not only for the basic biology of AAV but also for the optimal use of these vectors in human gene therapy. IMPORTANCE: The results of the studies described here not only have provided novel insights into some of the critical steps in the life cycle of a human virus, the adeno-associated virus (AAV), that causes no known disease but have also led to the development of novel recombinant AAV vectors which are more efficient in allowing increased levels of gene expression. Thus, these studies have significant implications for the potential use of these novel AAV vectors in human gene therapy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25355884      PMCID: PMC4300666          DOI: 10.1128/JVI.02581-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Promoters and control elements: designing expression cassettes for gene therapy.

Authors:  E D Papadakis; S A Nicklin; A H Baker; S J White
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

2.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

3.  Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV.

Authors:  R J Samulski; A Srivastava; K I Berns; N Muzyczka
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

4.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

5.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.

Authors:  D M McCarty; P E Monahan; R J Samulski
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

6.  Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo.

Authors:  Li Zhong; Linyuan Chen; Yanjun Li; Keyun Qing; Kirsten A Weigel-Kelley; Rebecca J Chan; Mervin C Yoder; Arun Srivastava
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

7.  Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

Authors:  Yi Lai; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

8.  Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo.

Authors:  Keyun Qing; Weiming Li; Li Zhong; Mengqun Tan; Jonathan Hansen; Kirsten A Weigel-Kelley; Linyuan Chen; Mervin C Yoder; Arun Srivastava
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Z Wang; H-I Ma; J Li; L Sun; J Zhang; X Xiao
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

10.  Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo.

Authors:  D M McCarty; H Fu; P E Monahan; C E Toulson; P Naik; R J Samulski
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

View more
  19 in total

1.  Productive life cycle of adeno-associated virus serotype 2 in the complete absence of a conventional polyadenylation signal.

Authors:  Lina Wang; Zifei Yin; Yuan Wang; Yuan Lu; Daniel Zhang; Arun Srivastava; Changquan Ling; George V Aslanidi; Chen Ling
Journal:  J Gen Virol       Date:  2015-06-30       Impact factor: 3.891

2.  Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.

Authors:  Arun Srivastava
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

Review 3.  AAV: An Overview of Unanswered Questions.

Authors:  Kenneth I Berns; Nicholas Muzyczka
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

4.  Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses.

Authors:  Chen Ling; Baozheng Li; Wenqin Ma; Arun Srivastava
Journal:  Hum Gene Ther Methods       Date:  2016-08       Impact factor: 2.396

5.  Sources of off-target expression from recombinase-dependent AAV vectors and mitigation with cross-over insensitive ATG-out vectors.

Authors:  Kyle B Fischer; Hannah K Collins; Edward M Callaway
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

6.  Nanopore sequencing of native adeno-associated virus (AAV) single-stranded DNA using a transposase-based rapid protocol.

Authors:  Marco T Radukic; David Brandt; Markus Haak; Kristian M Müller; Jörn Kalinowski
Journal:  NAR Genom Bioinform       Date:  2020-09-28

7.  A novel and highly efficient AAV6 mutant.

Authors:  Feifei Wang; Can Huang; Jinjing Cao; Xiaomei Liu; Dongxin Wang; Chun Zhang; Qin Chen
Journal:  Virus Genes       Date:  2017-12-27       Impact factor: 2.332

8.  Intracellular generation of single-strand template increases the knock-in efficiency by combining CRISPR/Cas9 with AAV.

Authors:  Qing Xiao; Taishan Min; Shuangping Ma; Lingna Hu; Hongyan Chen; Daru Lu
Journal:  Mol Genet Genomics       Date:  2018-04-18       Impact factor: 3.291

9.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

10.  The Adeno-Associated Virus Genome Packaging Puzzle.

Authors:  Chen Ling; Yuan Wang; Yuan Lu; Lina Wang; Giridhara R Jayandharan; George V Aslanidi; Baozheng Li; Binbin Cheng; Wenqin Ma; Thomas Lentz; Changquan Ling; Xiao Xiao; R Jude Samulski; Nicholas Muzyczka; Arun Srivastava
Journal:  J Mol Genet Med       Date:  2015-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.